Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Net Cash Flow (2016 - 2025)

Mimedx (MDXG) has disclosed Net Cash Flow for 15 consecutive years, with $24.0 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 45.29% to $24.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.7 million through Dec 2025, up 164.31% year-over-year, with the annual reading at $61.7 million for FY2025, 164.31% up from the prior year.
  • Net Cash Flow hit $24.0 million in Q4 2025 for Mimedx, up from $23.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $24.0 million in Q4 2025 to a low of -$33.5 million in Q1 2024.
  • Historically, Net Cash Flow has averaged $4.5 million across 5 years, with a median of $3.2 million in 2022.
  • Biggest five-year swings in Net Cash Flow: surged 466.19% in 2023 and later crashed 41274.07% in 2024.
  • Year by year, Net Cash Flow stood at -$3.5 million in 2021, then skyrocketed by 175.31% to $2.7 million in 2022, then soared by 239.04% to $9.0 million in 2023, then surged by 83.87% to $16.5 million in 2024, then skyrocketed by 45.29% to $24.0 million in 2025.
  • Business Quant data shows Net Cash Flow for MDXG at $24.0 million in Q4 2025, $23.2 million in Q3 2025, and $12.4 million in Q2 2025.